Advantages of intraperitoneal chemotherapy in treatment of ovarian cancer peritoneal carcinomatosis

Abstract

The purpose of research is a comparison of the combined antitumor effects of cytotoxic drugs used in the treatment of ovarian cancer, when administered intraperitoneally, with the effects of these drugs in mono-treatment. The study was conducted in 132 Wistar female rats inoculated intraperitoneally with ascitic tumor of the ovary. At 48 hours after inoculation of the ovarian tumor rats were administered once intraperitoneally with drugs at maximum tolerated doses, dioxadet 1.5 mg/kg of body weight, cisplatin 4 mg/kg, cyclophosphamide 100 mg/kg, paclitaxel 5 mg/kg, gemcitabine 50 mg/kg, or a combination of these drugs in half doses. Antitumor effects of the treatment were estimated by increase in survival time comparing median survival time of rats in different groups. Combinations dioxadet with cisplatin”, dioxadet with cyclophosphamide, and dioxadet with paclitaxel” have additive antitumor effects in comparison with the effects of these drugs administered separately. Combination dioxadet with gemcitabine did not increase the antitumor activity of the drugs.